nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Prednisone—Crohn's disease	0.922	1	CpDpCtD
Dihydroergotamine—Stiffness—Mesalazine—Crohn's disease	0.00212	0.041	CcSEcCtD
Dihydroergotamine—Lacrimal disorder—Mesalazine—Crohn's disease	0.0018	0.0349	CcSEcCtD
Dihydroergotamine—Parosmia—Mesalazine—Crohn's disease	0.00124	0.024	CcSEcCtD
Dihydroergotamine—Rigors—Azathioprine—Crohn's disease	0.00108	0.021	CcSEcCtD
Dihydroergotamine—Musculoskeletal stiffness—Mesalazine—Crohn's disease	0.000899	0.0174	CcSEcCtD
Dihydroergotamine—Trauma—Prednisone—Crohn's disease	0.000897	0.0173	CcSEcCtD
Dihydroergotamine—Vaginal inflammation—Mesalazine—Crohn's disease	0.000807	0.0156	CcSEcCtD
Dihydroergotamine—Cystitis noninfective—Mesalazine—Crohn's disease	0.000788	0.0152	CcSEcCtD
Dihydroergotamine—Influenza like illness—Mesalazine—Crohn's disease	0.000783	0.0151	CcSEcCtD
Dihydroergotamine—Cystitis—Mesalazine—Crohn's disease	0.000779	0.0151	CcSEcCtD
Dihydroergotamine—Vaginal infection—Mesalazine—Crohn's disease	0.000762	0.0147	CcSEcCtD
Dihydroergotamine—Bladder pain—Mesalazine—Crohn's disease	0.000729	0.0141	CcSEcCtD
Dihydroergotamine—Ear pain—Mesalazine—Crohn's disease	0.000686	0.0133	CcSEcCtD
Dihydroergotamine—Eye pain—Mesalazine—Crohn's disease	0.000649	0.0125	CcSEcCtD
Dihydroergotamine—Migraine—Mesalazine—Crohn's disease	0.000576	0.0111	CcSEcCtD
Dihydroergotamine—Face oedema—Mesalazine—Crohn's disease	0.000565	0.0109	CcSEcCtD
Dihydroergotamine—Arthralgia—Mercaptopurine—Crohn's disease	0.000553	0.0107	CcSEcCtD
Dihydroergotamine—Oedema—Mercaptopurine—Crohn's disease	0.00053	0.0102	CcSEcCtD
Dihydroergotamine—Cramp muscle—Mesalazine—Crohn's disease	0.000527	0.0102	CcSEcCtD
Dihydroergotamine—Petechiae—Prednisone—Crohn's disease	0.000519	0.01	CcSEcCtD
Dihydroergotamine—Dysphagia—Mesalazine—Crohn's disease	0.000506	0.00978	CcSEcCtD
Dihydroergotamine—Anorexia—Mercaptopurine—Crohn's disease	0.000506	0.00977	CcSEcCtD
Dihydroergotamine—Bronchospasm—Mesalazine—Crohn's disease	0.000498	0.00962	CcSEcCtD
Dihydroergotamine—Angina pectoris—Mesalazine—Crohn's disease	0.000493	0.00953	CcSEcCtD
Dihydroergotamine—Bronchitis—Mesalazine—Crohn's disease	0.000487	0.00941	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000483	0.00934	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00047	0.00909	CcSEcCtD
Dihydroergotamine—Pollakiuria—Mesalazine—Crohn's disease	0.000468	0.00904	CcSEcCtD
Dihydroergotamine—Decreased appetite—Mercaptopurine—Crohn's disease	0.000461	0.00891	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Mesalazine—Crohn's disease	0.000439	0.00848	CcSEcCtD
Dihydroergotamine—Hiccups—Prednisone—Crohn's disease	0.000427	0.00825	CcSEcCtD
Dihydroergotamine—Epistaxis—Mesalazine—Crohn's disease	0.000426	0.00823	CcSEcCtD
Dihydroergotamine—Sinusitis—Mesalazine—Crohn's disease	0.000423	0.00818	CcSEcCtD
Dihydroergotamine—Body temperature increased—Mercaptopurine—Crohn's disease	0.000419	0.0081	CcSEcCtD
Dihydroergotamine—Rhinitis—Mesalazine—Crohn's disease	0.000406	0.00785	CcSEcCtD
Dihydroergotamine—Pharyngitis—Mesalazine—Crohn's disease	0.000402	0.00777	CcSEcCtD
Dihydroergotamine—Chills—Azathioprine—Crohn's disease	0.000399	0.00771	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000391	0.00755	CcSEcCtD
Dihydroergotamine—Tinnitus—Mesalazine—Crohn's disease	0.000378	0.0073	CcSEcCtD
Dihydroergotamine—Hyperkinesia—Prednisone—Crohn's disease	0.000372	0.00719	CcSEcCtD
Dihydroergotamine—Euphoric mood—Prednisone—Crohn's disease	0.000367	0.00709	CcSEcCtD
Dihydroergotamine—Chills—Mesalazine—Crohn's disease	0.000364	0.00703	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mercaptopurine—Crohn's disease	0.000363	0.00701	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Azathioprine—Crohn's disease	0.000359	0.00694	CcSEcCtD
Dihydroergotamine—Malaise—Azathioprine—Crohn's disease	0.000349	0.00675	CcSEcCtD
Dihydroergotamine—Tension—Mesalazine—Crohn's disease	0.000346	0.00669	CcSEcCtD
Dihydroergotamine—Nervousness—Mesalazine—Crohn's disease	0.000343	0.00662	CcSEcCtD
Dihydroergotamine—Muscle spasms—Mesalazine—Crohn's disease	0.000339	0.00655	CcSEcCtD
Dihydroergotamine—Vomiting—Mercaptopurine—Crohn's disease	0.000337	0.00652	CcSEcCtD
Dihydroergotamine—Injury—Prednisone—Crohn's disease	0.000337	0.00651	CcSEcCtD
Dihydroergotamine—Rash—Mercaptopurine—Crohn's disease	0.000334	0.00646	CcSEcCtD
Dihydroergotamine—Dermatitis—Mercaptopurine—Crohn's disease	0.000334	0.00646	CcSEcCtD
Dihydroergotamine—Tremor—Mesalazine—Crohn's disease	0.00033	0.00639	CcSEcCtD
Dihydroergotamine—Arthralgia—Azathioprine—Crohn's disease	0.00033	0.00637	CcSEcCtD
Dihydroergotamine—Myalgia—Azathioprine—Crohn's disease	0.00033	0.00637	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Mesalazine—Crohn's disease	0.000327	0.00632	CcSEcCtD
Dihydroergotamine—Discomfort—Azathioprine—Crohn's disease	0.000326	0.00629	CcSEcCtD
Dihydroergotamine—Malaise—Mesalazine—Crohn's disease	0.000318	0.00615	CcSEcCtD
Dihydroergotamine—Vertigo—Mesalazine—Crohn's disease	0.000317	0.00612	CcSEcCtD
Dihydroergotamine—Nausea—Mercaptopurine—Crohn's disease	0.000315	0.00609	CcSEcCtD
Dihydroergotamine—Palpitations—Mesalazine—Crohn's disease	0.000312	0.00602	CcSEcCtD
Dihydroergotamine—Hypertension—Mesalazine—Crohn's disease	0.000304	0.00588	CcSEcCtD
Dihydroergotamine—Myalgia—Mesalazine—Crohn's disease	0.0003	0.0058	CcSEcCtD
Dihydroergotamine—Arthralgia—Mesalazine—Crohn's disease	0.0003	0.0058	CcSEcCtD
Dihydroergotamine—Anxiety—Mesalazine—Crohn's disease	0.000299	0.00578	CcSEcCtD
Dihydroergotamine—Face oedema—Prednisone—Crohn's disease	0.000299	0.00578	CcSEcCtD
Dihydroergotamine—Discomfort—Mesalazine—Crohn's disease	0.000297	0.00573	CcSEcCtD
Dihydroergotamine—Hypotension—Azathioprine—Crohn's disease	0.000295	0.00571	CcSEcCtD
Dihydroergotamine—Dry mouth—Mesalazine—Crohn's disease	0.000294	0.00567	CcSEcCtD
Dihydroergotamine—Confusional state—Mesalazine—Crohn's disease	0.00029	0.00561	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000288	0.00556	CcSEcCtD
Dihydroergotamine—Oedema—Mesalazine—Crohn's disease	0.000288	0.00556	CcSEcCtD
Dihydroergotamine—Shock—Mesalazine—Crohn's disease	0.000283	0.00547	CcSEcCtD
Dihydroergotamine—Tachycardia—Mesalazine—Crohn's disease	0.000281	0.00543	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Mesalazine—Crohn's disease	0.000278	0.00538	CcSEcCtD
Dihydroergotamine—Anorexia—Mesalazine—Crohn's disease	0.000274	0.0053	CcSEcCtD
Dihydroergotamine—Muscular weakness—Prednisone—Crohn's disease	0.000273	0.00528	CcSEcCtD
Dihydroergotamine—Hypotension—Mesalazine—Crohn's disease	0.000269	0.0052	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000262	0.00507	CcSEcCtD
Dihydroergotamine—Sweating increased—Prednisone—Crohn's disease	0.000261	0.00504	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Azathioprine—Crohn's disease	0.00026	0.00503	CcSEcCtD
Dihydroergotamine—Insomnia—Mesalazine—Crohn's disease	0.00026	0.00503	CcSEcCtD
Dihydroergotamine—Paraesthesia—Mesalazine—Crohn's disease	0.000258	0.00499	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000258	0.00499	CcSEcCtD
Dihydroergotamine—Dyspnoea—Mesalazine—Crohn's disease	0.000257	0.00496	CcSEcCtD
Dihydroergotamine—Somnolence—Mesalazine—Crohn's disease	0.000256	0.00495	CcSEcCtD
Dihydroergotamine—Dyspepsia—Mesalazine—Crohn's disease	0.000253	0.0049	CcSEcCtD
Dihydroergotamine—Decreased appetite—Mesalazine—Crohn's disease	0.00025	0.00484	CcSEcCtD
Dihydroergotamine—Body temperature increased—Azathioprine—Crohn's disease	0.00025	0.00483	CcSEcCtD
Dihydroergotamine—Abdominal pain—Azathioprine—Crohn's disease	0.00025	0.00483	CcSEcCtD
Dihydroergotamine—Fatigue—Mesalazine—Crohn's disease	0.000248	0.0048	CcSEcCtD
Dihydroergotamine—Pain—Mesalazine—Crohn's disease	0.000246	0.00476	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Mesalazine—Crohn's disease	0.000237	0.00458	CcSEcCtD
Dihydroergotamine—Acute coronary syndrome—Prednisone—Crohn's disease	0.000235	0.00455	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000235	0.00455	CcSEcCtD
Dihydroergotamine—Myocardial infarction—Prednisone—Crohn's disease	0.000234	0.00452	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Azathioprine—Crohn's disease	0.000233	0.0045	CcSEcCtD
Dihydroergotamine—Urticaria—Mesalazine—Crohn's disease	0.000229	0.00442	CcSEcCtD
Dihydroergotamine—Body temperature increased—Mesalazine—Crohn's disease	0.000228	0.0044	CcSEcCtD
Dihydroergotamine—Abdominal pain—Mesalazine—Crohn's disease	0.000228	0.0044	CcSEcCtD
Dihydroergotamine—Diarrhoea—Azathioprine—Crohn's disease	0.000216	0.00418	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Mesalazine—Crohn's disease	0.000212	0.0041	CcSEcCtD
Dihydroergotamine—Dizziness—Azathioprine—Crohn's disease	0.000209	0.00404	CcSEcCtD
Dihydroergotamine—Asthenia—Mesalazine—Crohn's disease	0.000207	0.00399	CcSEcCtD
Dihydroergotamine—Pruritus—Mesalazine—Crohn's disease	0.000204	0.00394	CcSEcCtD
Dihydroergotamine—Vomiting—Azathioprine—Crohn's disease	0.000201	0.00388	CcSEcCtD
Dihydroergotamine—Rash—Azathioprine—Crohn's disease	0.000199	0.00385	CcSEcCtD
Dihydroergotamine—Dermatitis—Azathioprine—Crohn's disease	0.000199	0.00385	CcSEcCtD
Dihydroergotamine—Flushing—Prednisone—Crohn's disease	0.000199	0.00384	CcSEcCtD
Dihydroergotamine—Headache—Azathioprine—Crohn's disease	0.000198	0.00383	CcSEcCtD
Dihydroergotamine—Diarrhoea—Mesalazine—Crohn's disease	0.000197	0.00381	CcSEcCtD
Dihydroergotamine—Dizziness—Mesalazine—Crohn's disease	0.00019	0.00368	CcSEcCtD
Dihydroergotamine—Nausea—Azathioprine—Crohn's disease	0.000188	0.00363	CcSEcCtD
Dihydroergotamine—Vomiting—Mesalazine—Crohn's disease	0.000183	0.00354	CcSEcCtD
Dihydroergotamine—Rash—Mesalazine—Crohn's disease	0.000181	0.00351	CcSEcCtD
Dihydroergotamine—Dermatitis—Mesalazine—Crohn's disease	0.000181	0.0035	CcSEcCtD
Dihydroergotamine—Headache—Mesalazine—Crohn's disease	0.00018	0.00348	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Prednisone—Crohn's disease	0.000173	0.00335	CcSEcCtD
Dihydroergotamine—Agitation—Prednisone—Crohn's disease	0.000171	0.00331	CcSEcCtD
Dihydroergotamine—Nausea—Mesalazine—Crohn's disease	0.000171	0.0033	CcSEcCtD
Dihydroergotamine—Malaise—Prednisone—Crohn's disease	0.000168	0.00325	CcSEcCtD
Dihydroergotamine—Vertigo—Prednisone—Crohn's disease	0.000168	0.00324	CcSEcCtD
Dihydroergotamine—Hypertension—Prednisone—Crohn's disease	0.000161	0.00311	CcSEcCtD
Dihydroergotamine—Myalgia—Prednisone—Crohn's disease	0.000159	0.00307	CcSEcCtD
Dihydroergotamine—Arthralgia—Prednisone—Crohn's disease	0.000159	0.00307	CcSEcCtD
Dihydroergotamine—Anxiety—Prednisone—Crohn's disease	0.000158	0.00306	CcSEcCtD
Dihydroergotamine—Discomfort—Prednisone—Crohn's disease	0.000157	0.00303	CcSEcCtD
Dihydroergotamine—Oedema—Prednisone—Crohn's disease	0.000152	0.00294	CcSEcCtD
Dihydroergotamine—Shock—Prednisone—Crohn's disease	0.00015	0.0029	CcSEcCtD
Dihydroergotamine—Tachycardia—Prednisone—Crohn's disease	0.000149	0.00287	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Prednisone—Crohn's disease	0.000147	0.00285	CcSEcCtD
Dihydroergotamine—Anorexia—Prednisone—Crohn's disease	0.000145	0.00281	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000139	0.00268	CcSEcCtD
Dihydroergotamine—Insomnia—Prednisone—Crohn's disease	0.000138	0.00266	CcSEcCtD
Dihydroergotamine—Paraesthesia—Prednisone—Crohn's disease	0.000137	0.00264	CcSEcCtD
Dihydroergotamine—Dyspepsia—Prednisone—Crohn's disease	0.000134	0.00259	CcSEcCtD
Dihydroergotamine—Decreased appetite—Prednisone—Crohn's disease	0.000132	0.00256	CcSEcCtD
Dihydroergotamine—Fatigue—Prednisone—Crohn's disease	0.000131	0.00254	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Prednisone—Crohn's disease	0.000125	0.00243	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Prednisone—Crohn's disease	0.000125	0.00241	CcSEcCtD
Dihydroergotamine—Urticaria—Prednisone—Crohn's disease	0.000121	0.00234	CcSEcCtD
Dihydroergotamine—Abdominal pain—Prednisone—Crohn's disease	0.00012	0.00233	CcSEcCtD
Dihydroergotamine—Body temperature increased—Prednisone—Crohn's disease	0.00012	0.00233	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Prednisone—Crohn's disease	0.000112	0.00217	CcSEcCtD
Dihydroergotamine—Asthenia—Prednisone—Crohn's disease	0.000109	0.00211	CcSEcCtD
Dihydroergotamine—Pruritus—Prednisone—Crohn's disease	0.000108	0.00208	CcSEcCtD
Dihydroergotamine—Diarrhoea—Prednisone—Crohn's disease	0.000104	0.00201	CcSEcCtD
Dihydroergotamine—Dizziness—Prednisone—Crohn's disease	0.000101	0.00195	CcSEcCtD
Dihydroergotamine—Vomiting—Prednisone—Crohn's disease	9.68e-05	0.00187	CcSEcCtD
Dihydroergotamine—Rash—Prednisone—Crohn's disease	9.6e-05	0.00186	CcSEcCtD
Dihydroergotamine—Dermatitis—Prednisone—Crohn's disease	9.59e-05	0.00185	CcSEcCtD
Dihydroergotamine—Headache—Prednisone—Crohn's disease	9.54e-05	0.00184	CcSEcCtD
Dihydroergotamine—Nausea—Prednisone—Crohn's disease	9.05e-05	0.00175	CcSEcCtD
Dihydroergotamine—HTR6—Signaling Pathways—CCR9—Crohn's disease	3.38e-05	0.00129	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SEL1L—Crohn's disease	3.38e-05	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR9—Crohn's disease	3.36e-05	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PTGER4—Crohn's disease	3.36e-05	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PTGER4—Crohn's disease	3.34e-05	0.00127	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR9—Crohn's disease	3.33e-05	0.00127	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PTGER4—Crohn's disease	3.32e-05	0.00126	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TAGAP—Crohn's disease	3.31e-05	0.00126	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR9—Crohn's disease	3.29e-05	0.00125	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PTGER4—Crohn's disease	3.25e-05	0.00123	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—GPR65—Crohn's disease	3.15e-05	0.0012	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—IL3—Crohn's disease	3.13e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	3.13e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—GPR65—Crohn's disease	3.12e-05	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—IL3—Crohn's disease	3.11e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PLA2G4F—Crohn's disease	3.11e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	3.11e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—GPR65—Crohn's disease	3.1e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CCR6—Crohn's disease	3.09e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR9—Crohn's disease	3.09e-05	0.00117	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GPR65—Crohn's disease	3.06e-05	0.00116	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PTGER4—Crohn's disease	3.05e-05	0.00116	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—IL3—Crohn's disease	3.05e-05	0.00116	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	3.04e-05	0.00116	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—RASGRP1—Crohn's disease	3.03e-05	0.00115	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—RASGRP1—Crohn's disease	3.01e-05	0.00114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ACKR2—Crohn's disease	3e-05	0.00114	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—ITGA4—Crohn's disease	2.96e-05	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—RASGRP1—Crohn's disease	2.95e-05	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—CXCL8—Crohn's disease	2.91e-05	0.00111	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RSPO3—Crohn's disease	2.89e-05	0.0011	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IL3—Crohn's disease	2.89e-05	0.0011	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GPR65—Crohn's disease	2.87e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—IL3—Crohn's disease	2.86e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	2.86e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL3—Crohn's disease	2.85e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MLN—Crohn's disease	2.84e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—Crohn's disease	2.83e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL3—Crohn's disease	2.82e-05	0.00107	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—TNF—Crohn's disease	2.81e-05	0.00107	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCR6—Crohn's disease	2.81e-05	0.00107	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—RASGRP1—Crohn's disease	2.79e-05	0.00106	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—RASGRP1—Crohn's disease	2.77e-05	0.00105	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL3—Crohn's disease	2.77e-05	0.00105	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—RASGRP1—Crohn's disease	2.75e-05	0.00105	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	2.75e-05	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SEL1L—Crohn's disease	2.74e-05	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—RASGRP1—Crohn's disease	2.73e-05	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PTGER4—Crohn's disease	2.72e-05	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—RASGRP1—Crohn's disease	2.67e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTMR3—Crohn's disease	2.64e-05	0.001	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—TNF—Crohn's disease	2.64e-05	0.001	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	2.64e-05	0.001	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TAGAP—Crohn's disease	2.6e-05	0.000988	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL3—Crohn's disease	2.6e-05	0.000987	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—RASGRP1—Crohn's disease	2.51e-05	0.000955	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR9—Crohn's disease	2.51e-05	0.000952	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PTGER4—Crohn's disease	2.47e-05	0.00094	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CCR6—Crohn's disease	2.43e-05	0.000924	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	2.43e-05	0.000923	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—CXCL8—Crohn's disease	2.38e-05	0.000906	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—CXCL8—Crohn's disease	2.36e-05	0.000899	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GPR65—Crohn's disease	2.33e-05	0.000885	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—IL3—Crohn's disease	2.32e-05	0.000882	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	2.32e-05	0.000881	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—CXCL8—Crohn's disease	2.32e-05	0.00088	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—CXCL8—Crohn's disease	2.29e-05	0.00087	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—IL6—Crohn's disease	2.27e-05	0.000863	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RSPO3—Crohn's disease	2.27e-05	0.000863	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—RASGRP1—Crohn's disease	2.24e-05	0.000853	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCR6—Crohn's disease	2.24e-05	0.000852	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR6—Crohn's disease	2.22e-05	0.000846	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR6—Crohn's disease	2.21e-05	0.000839	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—IL2RA—Crohn's disease	2.2e-05	0.000834	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—IL2RA—Crohn's disease	2.18e-05	0.000828	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR6—Crohn's disease	2.18e-05	0.000828	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—CXCL8—Crohn's disease	2.18e-05	0.000827	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	2.17e-05	0.000824	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SEL1L—Crohn's disease	2.15e-05	0.000818	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PLA2G4F—Crohn's disease	2.15e-05	0.000817	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PTGER4—Crohn's disease	2.14e-05	0.000814	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—IL2RA—Crohn's disease	2.13e-05	0.000811	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL3—Crohn's disease	2.11e-05	0.000801	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—FADS1—Crohn's disease	2.06e-05	0.000782	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR6—Crohn's disease	2.05e-05	0.000778	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—RASGRP1—Crohn's disease	2.04e-05	0.000775	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RBX1—Crohn's disease	2.03e-05	0.000771	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IL2RA—Crohn's disease	2.02e-05	0.000768	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RBX1—Crohn's disease	2.01e-05	0.000765	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—IL2RA—Crohn's disease	2e-05	0.000762	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL2RA—Crohn's disease	1.99e-05	0.000758	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL2RA—Crohn's disease	1.98e-05	0.000752	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PTGER4—Crohn's disease	1.97e-05	0.00075	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RBX1—Crohn's disease	1.97e-05	0.000749	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR9—Crohn's disease	1.97e-05	0.000748	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PTGER4—Crohn's disease	1.96e-05	0.000745	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PTGER4—Crohn's disease	1.94e-05	0.000739	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL2RA—Crohn's disease	1.94e-05	0.000736	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GPX4—Crohn's disease	1.93e-05	0.000733	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	1.93e-05	0.000733	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PTGER4—Crohn's disease	1.92e-05	0.000729	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GCKR—Crohn's disease	1.86e-05	0.000708	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RBX1—Crohn's disease	1.85e-05	0.000703	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GPR65—Crohn's disease	1.83e-05	0.000696	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTMR3—Crohn's disease	1.83e-05	0.000694	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL3—Crohn's disease	1.82e-05	0.000693	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	1.82e-05	0.000692	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL2RA—Crohn's disease	1.82e-05	0.000692	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PTGER4—Crohn's disease	1.8e-05	0.000685	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—UBE2D1—Crohn's disease	1.78e-05	0.000676	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—UBE2D1—Crohn's disease	1.76e-05	0.000671	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—CXCL8—Crohn's disease	1.76e-05	0.000671	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—RASGRP1—Crohn's disease	1.76e-05	0.00067	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—UBE2D1—Crohn's disease	1.73e-05	0.000657	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RIPK2—Crohn's disease	1.72e-05	0.000655	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RIPK2—Crohn's disease	1.71e-05	0.00065	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL3—Crohn's disease	1.68e-05	0.000639	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RIPK2—Crohn's disease	1.68e-05	0.000637	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL3—Crohn's disease	1.67e-05	0.000634	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR6—Crohn's disease	1.66e-05	0.000631	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL3—Crohn's disease	1.66e-05	0.000629	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL3—Crohn's disease	1.63e-05	0.000621	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RASGRP1—Crohn's disease	1.63e-05	0.000618	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—IL2RA—Crohn's disease	1.63e-05	0.000618	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—UBE2D1—Crohn's disease	1.62e-05	0.000617	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RASGRP1—Crohn's disease	1.61e-05	0.000613	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—RASGRP1—Crohn's disease	1.6e-05	0.000609	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RASGRP1—Crohn's disease	1.58e-05	0.000601	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RIPK2—Crohn's disease	1.57e-05	0.000598	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL3—Crohn's disease	1.53e-05	0.000583	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RBX1—Crohn's disease	1.5e-05	0.00057	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RASGRP1—Crohn's disease	1.48e-05	0.000564	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL2RA—Crohn's disease	1.48e-05	0.000561	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—JAK2—Crohn's disease	1.48e-05	0.000561	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SOCS1—Crohn's disease	1.47e-05	0.00056	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—JAK2—Crohn's disease	1.46e-05	0.000557	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SOCS1—Crohn's disease	1.46e-05	0.000556	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—ALB—Crohn's disease	1.46e-05	0.000555	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PTGER4—Crohn's disease	1.46e-05	0.000555	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—JAK2—Crohn's disease	1.43e-05	0.000545	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SOCS1—Crohn's disease	1.43e-05	0.000544	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—FADS1—Crohn's disease	1.42e-05	0.000541	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—TYK2—Crohn's disease	1.4e-05	0.000534	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—TYK2—Crohn's disease	1.39e-05	0.00053	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—CXCL8—Crohn's disease	1.39e-05	0.000527	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—TYK2—Crohn's disease	1.36e-05	0.000519	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—JAK2—Crohn's disease	1.36e-05	0.000516	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—JAK2—Crohn's disease	1.35e-05	0.000512	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CXCL8—Crohn's disease	1.35e-05	0.000512	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SOCS1—Crohn's disease	1.34e-05	0.000511	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—JAK2—Crohn's disease	1.34e-05	0.000509	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CXCL8—Crohn's disease	1.34e-05	0.000508	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX4—Crohn's disease	1.33e-05	0.000507	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—JAK2—Crohn's disease	1.33e-05	0.000505	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	1.32e-05	0.000503	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—UBE2D1—Crohn's disease	1.32e-05	0.0005	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CXCL8—Crohn's disease	1.31e-05	0.000497	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR6—Crohn's disease	1.3e-05	0.000496	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—JAK2—Crohn's disease	1.3e-05	0.000495	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.3e-05	0.000495	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GCKR—Crohn's disease	1.29e-05	0.000489	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—TYK2—Crohn's disease	1.28e-05	0.000487	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—IL2RA—Crohn's disease	1.28e-05	0.000486	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RIPK2—Crohn's disease	1.28e-05	0.000485	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SMAD3—Crohn's disease	1.27e-05	0.000483	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SMAD3—Crohn's disease	1.26e-05	0.00048	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL3—Crohn's disease	1.24e-05	0.000473	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SMAD3—Crohn's disease	1.24e-05	0.00047	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CXCL8—Crohn's disease	1.23e-05	0.000467	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—JAK2—Crohn's disease	1.22e-05	0.000465	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CXCL8—Crohn's disease	1.22e-05	0.000465	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CXCL8—Crohn's disease	1.21e-05	0.000461	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RASGRP1—Crohn's disease	1.2e-05	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CXCL8—Crohn's disease	1.19e-05	0.000452	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RBX1—Crohn's disease	1.18e-05	0.000448	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL2RA—Crohn's disease	1.18e-05	0.000448	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL2RA—Crohn's disease	1.17e-05	0.000444	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SMAD3—Crohn's disease	1.16e-05	0.000441	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL2RA—Crohn's disease	1.16e-05	0.000441	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTGER4—Crohn's disease	1.15e-05	0.000437	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL2RA—Crohn's disease	1.14e-05	0.000435	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.13e-05	0.000428	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CXCL8—Crohn's disease	1.12e-05	0.000424	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—JAK2—Crohn's disease	1.09e-05	0.000415	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SOCS1—Crohn's disease	1.09e-05	0.000415	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL2RA—Crohn's disease	1.07e-05	0.000409	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—TYK2—Crohn's disease	1.04e-05	0.000395	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—UBE2D1—Crohn's disease	1.03e-05	0.000393	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RIPK2—Crohn's disease	1e-05	0.000381	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CXCL8—Crohn's disease	9.97e-06	0.000379	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—JAK2—Crohn's disease	9.92e-06	0.000377	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL3—Crohn's disease	9.78e-06	0.000372	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RASGRP1—Crohn's disease	9.46e-06	0.00036	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SMAD3—Crohn's disease	9.41e-06	0.000358	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CXCL8—Crohn's disease	9.05e-06	0.000344	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—FADS1—Crohn's disease	8.77e-06	0.000333	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	8.75e-06	0.000332	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL2RA—Crohn's disease	8.72e-06	0.000331	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—JAK2—Crohn's disease	8.58e-06	0.000326	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SOCS1—Crohn's disease	8.57e-06	0.000326	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TYK2—Crohn's disease	8.3e-06	0.000315	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TYK2—Crohn's disease	8.23e-06	0.000313	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX4—Crohn's disease	8.21e-06	0.000312	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TYK2—Crohn's disease	8.17e-06	0.000311	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TYK2—Crohn's disease	8.06e-06	0.000306	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCKR—Crohn's disease	7.93e-06	0.000301	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JAK2—Crohn's disease	7.92e-06	0.000301	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JAK2—Crohn's disease	7.86e-06	0.000299	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—Crohn's disease	7.84e-06	0.000298	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—JAK2—Crohn's disease	7.8e-06	0.000296	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JAK2—Crohn's disease	7.69e-06	0.000292	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TYK2—Crohn's disease	7.57e-06	0.000288	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SMAD3—Crohn's disease	7.4e-06	0.000281	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JAK2—Crohn's disease	7.23e-06	0.000275	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—Crohn's disease	7.22e-06	0.000275	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—Crohn's disease	7.17e-06	0.000273	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—Crohn's disease	7.12e-06	0.00027	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—Crohn's disease	7.02e-06	0.000267	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—Crohn's disease	6.87e-06	0.000261	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL2RA—Crohn's disease	6.85e-06	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—Crohn's disease	6.82e-06	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—Crohn's disease	6.68e-06	0.000254	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—Crohn's disease	6.59e-06	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—Crohn's disease	6.27e-06	0.000238	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TYK2—Crohn's disease	6.14e-06	0.000233	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—Crohn's disease	5.92e-06	0.000225	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JAK2—Crohn's disease	5.86e-06	0.000223	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—Crohn's disease	5.81e-06	0.000221	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—Crohn's disease	5.77e-06	0.000219	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—Crohn's disease	5.65e-06	0.000215	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—Crohn's disease	5.35e-06	0.000203	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—Crohn's disease	5.3e-06	0.000202	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—Crohn's disease	5.18e-06	0.000197	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—Crohn's disease	5.09e-06	0.000193	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TYK2—Crohn's disease	4.83e-06	0.000183	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JAK2—Crohn's disease	4.61e-06	0.000175	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—Crohn's disease	4.3e-06	0.000163	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—Crohn's disease	4.2e-06	0.00016	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—Crohn's disease	4.1e-06	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—Crohn's disease	4.06e-06	0.000154	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—Crohn's disease	4.03e-06	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—Crohn's disease	4e-06	0.000152	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—Crohn's disease	3.94e-06	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—Crohn's disease	3.7e-06	0.000141	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—Crohn's disease	3.58e-06	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—Crohn's disease	3.38e-06	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—Crohn's disease	3e-06	0.000114	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—Crohn's disease	2.52e-06	9.59e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—Crohn's disease	2.36e-06	8.97e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—Crohn's disease	2.21e-06	8.39e-05	CbGpPWpGaD
